Cardiovascular events · proteinuric chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Doubling serum creatinine · proteinuric chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · proteinuric CKD
Aldosterone antagonists showed no clear difference in death compared with placebo or standard care (low certainty).
1 finding from 1 review
AKI · proteinuric chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proteinuria · proteinuric chronic kidney disease
1 finding from 1 review
GFR · proteinuric chronic kidney disease
1 finding from 1 review
Cardiovascular events · proteinuric CKD
Aldosterone antagonists showed no clear difference in cardiovascular events compared with placebo or standard care (low certainty).
1 finding from 1 review
Doubling serum creatinine · proteinuric CKD
Aldosterone antagonists showed no clear difference in doubling serum creatinine compared with placebo or standard care (low certainty).
1 finding from 1 review
AKI · proteinuric CKD
Aldosterone antagonists probably leads to higher AKI compared with placebo or standard care (moderate certainty).
1 finding from 1 review
Proteinuria · proteinuric CKD
1 finding from 1 review
eGFR · proteinuric CKD
1 finding from 1 review
Kidney failure · proteinuric CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (any cause) compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
All cardiovascular death · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
Cardiovascular and cerebrovascular morbidity · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower cardiovascular and cerebrovascular morbidity compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
Hyperkalaemia · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).
1 finding from 1 review
Gynaecomastia · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to higher gynaecomastia compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
Left ventricular mass · people with chronic kidney disease requiring dialysis
1 finding from 1 review
Death (any cause) ( · heart failure with chronic kidney disease
It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular mortality · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found